TERAZOL 3
LOE ApproachingNDAVAGINALSUPPOSITORY
Approved
May 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 3 is a vaginal suppository antifungal indicated for vulvovaginal candidiasis, a common yeast infection affecting millions of women annually. The product represents a foundational treatment in gynecological care with a well-established safety and efficacy profile since 1988.
LOE Approaching
Mature brand nearing loss of exclusivity; expect smaller, focused commercial teams prioritizing brand loyalty and OTC channel optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TERAZOL 3 offers stable, foundational pharma experience in a mature women's health market with established processes and loyal customer base. However, limited growth trajectory and minimal clinical activity suggest this role is better suited to professionals seeking operational expertise rather than innovation-driven career momentum.
Brand ManagerField Sales Representative
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.